Tempus AI (TEM) Q2 Revenue Surges 90%
Tempus AI (NASDAQ:TEM), a technology company that applies artificial intelligence to precision diagnostics and healthcare data, reported its Q2 2025 earnings on August 8, 2025. The period was marked by rapid growth and strong performance across its genomics and data services businesses. Revenue (GAAP) climbed to $314.6 million, surpassing the analyst consensus of $297.8 million. The non-GAAP loss per share narrowed to ($0.22), better than the expected ($0.23). Management lifted its full-year 2025 revenue forecast to $1.26 billion and now expects adjusted EBITDA profitability for fiscal 2025. The quarter reflected accelerating commercial momentum, significant margin expansion, and ongoing progress leveraging AI and data partnerships.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Tempus AI seeks to transform healthcare by using artificial intelligence for precision diagnostics. Its core business spans genomics testing -- including oncology and hereditary diagnostics -- and data services that leverage a vast clinical-molecular database. The company’s offerings help clinicians make more informed treatment decisions by integrating laboratory data with clinical histories and other medical information.
Source Fool.com
